NCT02381886View on ClinicalTrials.gov

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

March 6, 2015

Primary Completion Date

December 7, 2016

Study Completion Date

February 3, 2026

Conditions
Advanced Malignancies That Harbor IDHR132 Mutations
Interventions
DRUG

IDH305

Trial Locations (16)

3000

Novartis Investigative Site, Leuven

3004

Novartis Investigative Site, Melbourne

3050

Novartis Investigative Site, Parkville

10032

Columbia University Medical Center- New York Presbyterian Onc Dept., New York

Columbia University Medical Center, New York

50937

Novartis Investigative Site, Cologne

69120

Novartis Investigative Site, Heidelberg

77030

Uni Of TX MD Anderson Cancer Cntr, Houston

168583

Novartis Investigative Site, Singapore

02115

Dana Farber Cancer Institute SC (1), Boston

02215

Dana Farber Cancer Institute, Boston

M5G 2M9

Novartis Investigative Site, Toronto

07740

Novartis Investigative Site, Jena

3015 GD

Novartis Investigative Site, Rotterdam

3075 EA

ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55, Rotterdam

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY